PROCEPT BioRobotics Q1 2026: Reset Narrative Tested as Results Arrive

What happened

PROCEPT BioRobotics reported Q1 2026 results on April 29, 2026, marking the first full quarter under its commercial reset to align handpiece units with procedures and eliminate incentive-driven ordering. The report landed after management guided Q1 revenue of $79M–$82M and US procedures of 12,000–12,800, a critical checkpoint for the thesis that the 2026 growth reset is a one-time cleanup rather than demand deterioration. The DeepValue report flagged that credibility repair hinges on Q1 execution, with the bullish scenario requiring procedure growth and gross margin recovery. However, initial filings often spin positive spin; investors must scrutinize whether ASP discipline truly offset the loss of the 8%–16% historical handpiece buffer and whether gross margin shows a clear trajectory back toward the ~65% target. The next few quarters will determine if the investment case for profitability by Q4 2026 remains intact or if another guide-down is imminent.

Implication

The stock's re-rating depends on consistent execution in Q1 and Q2 2026. If US procedures hit the high end of guidance (12,800) and handpiece ASP sustains above $3,340, the bear case of structural revenue deceleration weakens. Conversely, any miss or lack of gross margin improvement (Q4 2025 was 60.6%) would signal deeper issues, making the $16 bear scenario more likely. The 2027 EBITDA target of +$25M–$30M hinges on these quarterly proofs.

Thesis delta

The thesis remains WAIT until Q1 2026 actuals confirm procedure momentum and pricing discipline. The Q1 print is the first audit of the reset; if it matches or beats the guided range, the probability of the base case ($30 value) increases. A miss would tilt toward the bear case ($16) and accelerate the 6-month re-assessment window.